News

  1. Home
  2. News

PolyBio Funds Spatial Metabolomic Mapping of Long COVID Tissues

New imaging study will pinpoint metabolic and mitochondrial abnormalities within tissues from people with Long COVIDMedford, MA — September 28, 2026...

Steve and Judy Pagliuca and Governor Maura Healey Accelerate Major Effort to Deliver Treatments for Long COVID

$15 million raised by a coalition of donors to advance diagnostics and clinical trials for Long COVID; with the infrastructure expanding...

New Study Reveals Substantial Tissue-Level Immune Dysfunction Near Persistent Viral Reservoirs in Long COVID

PolyBio-funded UCSF research finds persistent SARS-CoV-2 RNA alongside an altered gut immune response that may impair viral clearance. The findings provide a rationale for treatment strategies that target both persistent viral reservoirs and the tissue immune dysfunction that may allow them to remain.

New Study Identifies Overlapping Persistent Virus-Specific T Cell Responses in Long COVID

PolyBio-supported research provides new evidence that Long COVID is characterized by ongoing immune responses to persistent viral proteins, further supporting the...

Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Rapamycin Trial

PolyBio Research Foundation today announced new funding from the Balvi Fund to accelerate a clinical trial investigating low-dose rapamycin as a potential treatment for Long COVID. The funding will support an open-label extension phase that will allow all participants - including those initially randomized to placebo - to receive low-dose rapamycin during a defined follow-up period.

PolyBio-Supported Study Identifies Association Between HHV-6 Reactivation and Long COVID Severity

A collaborative study between the laboratory of Akiko Iwasaki at Yale University and the Icahn School of Medicine at Mount Sinai has identified a potential link between reactivation of the herpesvirus HHV-6 and Long COVID symptom severity. The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.

PolyBio Launches Commercialization Advisory Network to Accelerate Long COVID Diagnostics and Treatments

PolyBio Research Foundation today announced the formal launch of its Commercialization Advisory Network, a new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments.

Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative

PolyBio Research Foundation today announced a $10 million donation to support the Long COVID Cure Initiative (LCCI), a program designed to deliver treatments to millions of Long COVID patients by translating key academic findings into real-world diagnostic tests, faster and more targeted clinical trials, and accessible, patient-ready therapies.

New PolyBio-Supported Study Identifies Microclots, Endothelial Injury Markers, and Neutrophil Activation in Children and Young Adults with Long COVID

A new study supported by PolyBio Research Foundation studied children and young adults with Long COVID, providing evidence linking endovascular inflammation, increased quantity and size of fibrin-amyloid "microclots," and neutrophil activation, and finding detectable Spike protein in a subset.

PolyBio Expands Support for Extracellular Vesicle “Liquid Biopsy” Diagnostics for Chronic Infection

PolyBio Research Foundation is increasingly advancing a new class of diagnostics built on extracellular vesicle (EV)–based “liquid biopsy” technologies, supporting multiple new projects that aim to detect persistent infections and their biological impact in patients with Long COVID, Chronic Lyme Disease and related conditions.

VIPER Diagnostics Program Launches as first phase of PolyBio Long COVID Cure Initiative

Medford, MA, March 24, 2026 - PolyBio Research Foundation today announced the launch of VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort), the first large-scale program designed to rigorously validate diagnostic tests that measure SARS-CoV-2 persistence and other biological drivers of Long COVID.

PolyBio Scientist Speaks on Next-Generation Diagnostics at National HHS Conference on Women’s Health

Medford, MA, March 18, 2026 –  Researchers, clinicians, and policymakers gathered last week in Washington, DC for the inaugural HHS National...

Newsletter

PolyBio scientists are active at conferences and frequent guests on podcasts. Learn more about these events, get project updates, and meet the PolyBio team via our Newsletter.

Sign Up